Showing results (91-100 of 104) with videos related to
Sort By:
Pageof 11
Cancer Research|April 3, 2003
Characterization of sporadic colon cancer by patterns of genomic instabilityAjay Goel, Christian N Arnold, Donna Niedzwiecki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.Cancer|August 10, 2005
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.Journal of Neuro-Oncology|January 25, 2007
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins, Jennifer A Quinn, James J Vredenburgh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitutionDavid A Rizzieri, Liang Piu Koh, Gwynn D Long, et al.Neuro-Oncology|May 12, 2004
Phase 2 trial of BCNU plus irinotecan in adults with malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.Pageof 11